1. Sormani, MP, De Rossi, N, Schiavetti, I, et al. Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol 2021; 89: 780–789.
Google Scholar | Crossref | Medline2. Thornton, JR, Harel, A. Negative SARS-CoV-2 antibody testing following COVID-19 infection in two MS patients treated with ocrelizumab. Mult Scler Relat Disord 2020; 44: 102341.
Google Scholar | Crossref | Medline3. Achiron, A, Mandel, M, Dreyer-Alster, S, et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord 2021; 14: 17562864211012836.
Google Scholar | SAGE Journals | ISI4. Maarouf, A, Rico, A, Boutiere, C, et al. Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond? Neurol Neuroimmunol Neuroinflammation. 2020; 7(5) Available at: https://nn.neurology.org/content/7/5/e825 (Accessed November 19, 2021).
Google Scholar | Crossref | Medline5. Bar-Or, A, Calabresi, PAJ, Arnold, D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 2008; 63: 395–400.
Google Scholar | Crossref | Medline | ISI6. Hauser, SL, Waubant, E, Arnold, DL, et al. B-Cell depletion with rituximab in relapsing–remitting multiple sclerosis. N Engl J Med 2008; 358: 676–688.
Google Scholar | Crossref | Medline | ISI7. Salzer, J, Svenningsson, R, Alping, P, et al. Rituximab in multiple sclerosis. Neurology 2016; 87: 2074–2081.
Google Scholar | Crossref | Medline | ISI8. de Flon, P, Gunnarsson, M, Laurell, K, et al. Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab. Neurology 2016; 87: 141–147.
Google Scholar | Crossref | Medline | ISI9. Gallian, P, Pastorino, B, Morel, P, et al. Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors. Antiviral Res 2020; 181: 104880.
Google Scholar | Crossref | Medline10. Herishanu, Y, Avivi, I, Aharon, A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood 2021; 137: 3165–3173.
Google Scholar | Crossref | Medline11. Bonelli, MM, Mrak, D, Perkmann, T, et al. SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response. Ann Rheum Dis 2021; 80(10): 1355–1356.
Google Scholar | Crossref | Medline12. Sormani, MP, Inglese, M, Schiavetti, I, et al. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. EBioMedicine 2021; 72, Available at: https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00374-1/fulltext (Accessed November 19, 2021).
Google Scholar | Crossref | Medline13. Ali, A, Dwyer, D, Wu, Q, et al. Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies. Vaccine 2021; 39: 6111–6116.
Google Scholar | Crossref | Medline14. Strangfeld, A, Schäfer, M, Gianfrancesco, MA, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann. Rheum. Dis. 2021; 80(7):930–942.
Google Scholar15. Bange, EM, Han, NA, Wileyto, P, et al. CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med 2021; 27(7):1280–1289.
Google Scholar | Crossref | Medline16. Apostolidis, SA, Kakara, M, Painter, MM, et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med 2021.
Google Scholar | Crossref | Medline17. Ellwardt, E, Ellwardt, L, Bittner, S, et al. Monitoring B-cell repopulation after depletion therapy in neurologic patients. Neurology - Neuroimmunology Neuroinflammation 2018; 5(4), Available at: https://nn.neurology.org/content/5/4/e463 (Accessed November 19, 2021).
Google Scholar | Crossref18. Boremalm, M, Sundström, P, Salzer, J. Discontinuation and dose reduction of rituximab in relapsing-remitting multiple sclerosis. J Neurol 2021; 268(6):2161–2168.
Google Scholar | Crossref | Medline